TransCode Therapeutics, Inc.

RNAZNASDAQHealthcare● Active

$5.09

$-0.51(-9.11%)

Market Cap$4837032

P/E Ratio—

52W High$20.99

52W Low$3.82

Avg Volume46K

Open$5.54

Beta1.40

Cash on Hand Financials Revenue

TransCode Therapeutics, Inc. (RNAZ) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

RNAZ · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$17.8M▲ +206.5% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$17.8M

cashAndCashEquivalents

Short-Term Investments

shortTermInvestments

YoY Change vs Prior Year

+206.5%

vs prior fiscal year

Latest Quarter

$12.8M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$17.8MCash on Hand

Total Debt$0Total Debt

Net Cash / Net Debt+$17.8MNet Cash Position

Cash vs Debt Ratio

Cash 100%TransCode Therapeutics, Inc. cash as % of market cap: 368.27%% · MCap $0BDebt 0%

TransCode Therapeutics, Inc. has a net cash position of $17.8M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$17.8M − $0 = +$17.8M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

RNAZ annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

RNAZ cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$17.8M+206.5%

Dec 31, 2024FY$5.8M+110.0%

Dec 31, 2023FY$2.8M-44.4%

Dec 31, 2022FY$5.0M-76.1%

Dec 31, 2021FY$20.8M+2415.2%

RNAZ cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

RNAZ vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

TransCode Therapeutics, Inc.YOU

RNAZ

$17.8M$5M368.3%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

TransCode Therapeutics, Inc. (RNAZ) cash on hand as of December 31, 2025 is $17.8M, comprising $17.8M in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as TransCode Therapeutics, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as TransCode Therapeutics, Inc. cash reserves or cash position.

TransCode Therapeutics, Inc. annual cash on hand history shows increased +206.5% in 2025: increased +206.5% in 2025. TransCode Therapeutics, Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

TransCode Therapeutics, Inc. carries total debt of $0 against cash of $17.8M, resulting in a net cash position of +$17.8M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

RNAZ cash on hand · 5 questions

As of December 31, 2025, TransCode Therapeutics, Inc. (RNAZ) has $17,813,521 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $17,813,521 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $12,835,454. Data sourced from the annual 10-K filing via FMP.

RNAZ cash on handRNAZ cash reservesRNAZ cash 2025how much cash does RNAZ have

▸ Source: FMP /balance-sheet-statement · US GAAP · TransCode Therapeutics, Inc. · TransCode Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025